Pune, India

Prabakaran Kamalakannan


Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Prabakaran Kamalakannan: Innovator in Chroman Compounds

Introduction

Prabakaran Kamalakannan is a notable inventor based in Pune, India. He has made significant contributions to the field of chemistry, particularly in the synthesis of chroman compounds. His innovative approach has led to advancements that are both economically viable and environmentally friendly.

Latest Patents

Prabakaran holds a patent for a process for preparing chroman compounds. This process allows for the manufacturing of substituted chroman compounds in an economically scalable manner, without the use of pyrophoric reagents. The patent also discloses synthesis routes that do not require column chromatography purification steps. Additionally, it relates to the synthesis of the Calcium sensing receptor (CaSR) modulating agent, specifically 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid, along with its intermediates and pharmaceutically acceptable salts. Prabakaran has 1 patent to his name.

Career Highlights

Prabakaran is currently associated with Lupin, Inc., a prominent pharmaceutical company. His work focuses on innovative processes that enhance the efficiency and effectiveness of drug development. His expertise in chemistry has positioned him as a valuable asset in the field.

Collaborations

Prabakaran has collaborated with notable colleagues, including Rajender Kumar Kamboj and Shaji George Kochumalayil. These collaborations have fostered a productive environment for research and development, leading to significant advancements in their respective fields.

Conclusion

Prabakaran Kamalakannan is a distinguished inventor whose work in chroman compounds has made a substantial impact in the pharmaceutical industry. His innovative processes and collaborations continue to drive advancements in chemistry and drug development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…